DEFA14A: Ultragenyx Pharmaceuticals Inc. Sets Date for 2025 Annual Meeting, Outlines Proposals for Stockholder Vote

Ultragenyx Pharmaceuticals Inc. announces its 2025 Annual Meeting and provides details on proposals for stockholder voting, including director nominations, incentive plan approval, auditor ratification, and executive compensation.

Summary

• Ultragenyx Pharmaceuticals Inc. is holding its Annual Meeting in 2025.
• The meeting will take place on May 15, 2025, at 9:00 a.m. Pacific Time, virtually at www.virtualshareholdermeeting.com/RARE2025.
• Stockholders are invited to vote on several proposals.
• These proposals include the election of Matthew K. Fust and Amrit Ray, M.D. as directors.
• Also up for vote is the approval of the Second Amended and Restated 2023 Incentive Plan.
• Stockholders will also vote to ratify the selection of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
• An advisory vote to approve the compensation of named executive officers is also on the agenda.
• Stockholders can access meeting materials and vote online at www.ProxyVote.com.
• The deadline to vote is May 14, 2025, at 11:59 PM ET.
• Copies of the proxy materials can be requested until May 1, 2025.

Sentiment

Score: 7

Explanation: The document is a routine announcement of an annual meeting and proxy vote, which is generally neutral in sentiment. The proposals themselves could have positive or negative implications depending on shareholder perspectives.

Positives

• The announcement provides clear instructions for stockholders to access proxy materials and vote.
• Stockholders have the opportunity to influence key decisions regarding the company's governance and compensation practices.

Future Outlook

The document outlines the agenda for the upcoming annual meeting, indicating the company's focus on governance and shareholder engagement.

Industry Context

This announcement is standard practice for publicly traded companies, ensuring shareholders are informed and have the opportunity to vote on key company matters.

Stakeholder Impact

• Shareholders are directly impacted through their voting rights on key company decisions.
• The outcome of the votes can influence the company's direction and executive compensation.

Next Steps

• Stockholders should review the proxy materials.
• Stockholders should vote on the proposals by the deadline of May 14, 2025.

Key Dates

Keywords

Annual Meeting, Proxy Vote, Stockholders, Ultragenyx, Incentive Plan, Executive Compensation, Auditor Ratification, Director Nomination